Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer

Brian J. Davis, Thomas M. Pisansky, Bradley C. Leibovich

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Purpose of review: The use of adjuvant radiation therapy following prostatectomy is commonplace. The purpose of this review is to summarize completed and ongoing clinical trials and to review recent relevant studies and debates related to this subject. Recent findings: The routine use of adjuvant radiation therapy remains a controversial topic. Recent retrospective matched-pair analyses support its use in appropriately selected patients with positive margins, extraprostatic extension or seminal vesicle invasion, but interpretation of these and other data vary. Although the 5-year biochemical recurrence rate using adjuvant radiotherapy may be decreased from approximately 40 to 10% in patients with either positive margins or extraprostatic extension, its effect on cause-specific mortality is unclear. Two prospective randomized trials with cumulative enrollment of over 1400 patients have examined the role of adjuvant radiation therapy compared with observation following prostatectomy: one trial was a National Cancer Institute-sponsored Intergroup study coordinated by the Southwest Oncology Group, and the other was from the European Organization for Research and Treatment of Cancer. Currently, the Radiation Therapy Oncology Group is conducting a three-arm trial, with broadened stratification criteria as compared with previous trials. This ongoing trial examines the use of adjuvant radiotherapy with or without adjuvant androgen deprivation following prostatectomy and also androgen deprivation alone in patients at high risk for disease relapse. Summary: In lieu of data from completed randomized trials, indications for immediate adjuvant radiation therapy following prostatectomy exist and are supported by retrospective data with respect to reducing local and biochemical recurrence rates. However, data demonstrating an overall or cause-specific survival advantage for adjuvant radiotherapy as compared with delayed salvage therapy do not exist.

Original languageEnglish (US)
Pages (from-to)117-122
Number of pages6
JournalCurrent Opinion in Urology
Volume13
Issue number2
DOIs
StatePublished - Mar 2003

Fingerprint

Prostatectomy
Prostatic Neoplasms
Radiotherapy
Adjuvant Radiotherapy
Recurrence
Androgens
Matched-Pair Analysis
Salvage Therapy
Radiation Oncology
National Cancer Institute (U.S.)
Seminal Vesicles
Observation
Clinical Trials
Organizations
Survival
Mortality
Research
Neoplasms
Therapeutics

Keywords

  • Prostatectomy
  • Prostatic neoplasms
  • Radiation therapy

ASJC Scopus subject areas

  • Urology

Cite this

Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer. / Davis, Brian J.; Pisansky, Thomas M.; Leibovich, Bradley C.

In: Current Opinion in Urology, Vol. 13, No. 2, 03.2003, p. 117-122.

Research output: Contribution to journalArticle

Davis, Brian J. ; Pisansky, Thomas M. ; Leibovich, Bradley C. / Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer. In: Current Opinion in Urology. 2003 ; Vol. 13, No. 2. pp. 117-122.
@article{0435b6b950054e6f980fe2a69ea1776f,
title = "Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer",
abstract = "Purpose of review: The use of adjuvant radiation therapy following prostatectomy is commonplace. The purpose of this review is to summarize completed and ongoing clinical trials and to review recent relevant studies and debates related to this subject. Recent findings: The routine use of adjuvant radiation therapy remains a controversial topic. Recent retrospective matched-pair analyses support its use in appropriately selected patients with positive margins, extraprostatic extension or seminal vesicle invasion, but interpretation of these and other data vary. Although the 5-year biochemical recurrence rate using adjuvant radiotherapy may be decreased from approximately 40 to 10{\%} in patients with either positive margins or extraprostatic extension, its effect on cause-specific mortality is unclear. Two prospective randomized trials with cumulative enrollment of over 1400 patients have examined the role of adjuvant radiation therapy compared with observation following prostatectomy: one trial was a National Cancer Institute-sponsored Intergroup study coordinated by the Southwest Oncology Group, and the other was from the European Organization for Research and Treatment of Cancer. Currently, the Radiation Therapy Oncology Group is conducting a three-arm trial, with broadened stratification criteria as compared with previous trials. This ongoing trial examines the use of adjuvant radiotherapy with or without adjuvant androgen deprivation following prostatectomy and also androgen deprivation alone in patients at high risk for disease relapse. Summary: In lieu of data from completed randomized trials, indications for immediate adjuvant radiation therapy following prostatectomy exist and are supported by retrospective data with respect to reducing local and biochemical recurrence rates. However, data demonstrating an overall or cause-specific survival advantage for adjuvant radiotherapy as compared with delayed salvage therapy do not exist.",
keywords = "Prostatectomy, Prostatic neoplasms, Radiation therapy",
author = "Davis, {Brian J.} and Pisansky, {Thomas M.} and Leibovich, {Bradley C.}",
year = "2003",
month = "3",
doi = "10.1097/00042307-200303000-00006",
language = "English (US)",
volume = "13",
pages = "117--122",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer

AU - Davis, Brian J.

AU - Pisansky, Thomas M.

AU - Leibovich, Bradley C.

PY - 2003/3

Y1 - 2003/3

N2 - Purpose of review: The use of adjuvant radiation therapy following prostatectomy is commonplace. The purpose of this review is to summarize completed and ongoing clinical trials and to review recent relevant studies and debates related to this subject. Recent findings: The routine use of adjuvant radiation therapy remains a controversial topic. Recent retrospective matched-pair analyses support its use in appropriately selected patients with positive margins, extraprostatic extension or seminal vesicle invasion, but interpretation of these and other data vary. Although the 5-year biochemical recurrence rate using adjuvant radiotherapy may be decreased from approximately 40 to 10% in patients with either positive margins or extraprostatic extension, its effect on cause-specific mortality is unclear. Two prospective randomized trials with cumulative enrollment of over 1400 patients have examined the role of adjuvant radiation therapy compared with observation following prostatectomy: one trial was a National Cancer Institute-sponsored Intergroup study coordinated by the Southwest Oncology Group, and the other was from the European Organization for Research and Treatment of Cancer. Currently, the Radiation Therapy Oncology Group is conducting a three-arm trial, with broadened stratification criteria as compared with previous trials. This ongoing trial examines the use of adjuvant radiotherapy with or without adjuvant androgen deprivation following prostatectomy and also androgen deprivation alone in patients at high risk for disease relapse. Summary: In lieu of data from completed randomized trials, indications for immediate adjuvant radiation therapy following prostatectomy exist and are supported by retrospective data with respect to reducing local and biochemical recurrence rates. However, data demonstrating an overall or cause-specific survival advantage for adjuvant radiotherapy as compared with delayed salvage therapy do not exist.

AB - Purpose of review: The use of adjuvant radiation therapy following prostatectomy is commonplace. The purpose of this review is to summarize completed and ongoing clinical trials and to review recent relevant studies and debates related to this subject. Recent findings: The routine use of adjuvant radiation therapy remains a controversial topic. Recent retrospective matched-pair analyses support its use in appropriately selected patients with positive margins, extraprostatic extension or seminal vesicle invasion, but interpretation of these and other data vary. Although the 5-year biochemical recurrence rate using adjuvant radiotherapy may be decreased from approximately 40 to 10% in patients with either positive margins or extraprostatic extension, its effect on cause-specific mortality is unclear. Two prospective randomized trials with cumulative enrollment of over 1400 patients have examined the role of adjuvant radiation therapy compared with observation following prostatectomy: one trial was a National Cancer Institute-sponsored Intergroup study coordinated by the Southwest Oncology Group, and the other was from the European Organization for Research and Treatment of Cancer. Currently, the Radiation Therapy Oncology Group is conducting a three-arm trial, with broadened stratification criteria as compared with previous trials. This ongoing trial examines the use of adjuvant radiotherapy with or without adjuvant androgen deprivation following prostatectomy and also androgen deprivation alone in patients at high risk for disease relapse. Summary: In lieu of data from completed randomized trials, indications for immediate adjuvant radiation therapy following prostatectomy exist and are supported by retrospective data with respect to reducing local and biochemical recurrence rates. However, data demonstrating an overall or cause-specific survival advantage for adjuvant radiotherapy as compared with delayed salvage therapy do not exist.

KW - Prostatectomy

KW - Prostatic neoplasms

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=0037335179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037335179&partnerID=8YFLogxK

U2 - 10.1097/00042307-200303000-00006

DO - 10.1097/00042307-200303000-00006

M3 - Article

C2 - 12584471

AN - SCOPUS:0037335179

VL - 13

SP - 117

EP - 122

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 2

ER -